Compare DNUT & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNUT | IRWD |
|---|---|---|
| Founded | 1937 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.5M | 526.7M |
| IPO Year | 2021 | 2009 |
| Metric | DNUT | IRWD |
|---|---|---|
| Price | $3.61 | $4.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $4.72 | ★ $7.67 |
| AVG Volume (30 Days) | 1.7M | ★ 1.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.99% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $1,522,616,000.00 | $298,276,000.00 |
| Revenue This Year | $0.55 | $57.95 |
| Revenue Next Year | $3.59 | $4.39 |
| P/E Ratio | ★ N/A | $28.87 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $2.58 | $0.55 |
| 52 Week High | $5.73 | $5.78 |
| Indicator | DNUT | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 67.36 |
| Support Level | $3.17 | $3.07 |
| Resistance Level | $3.87 | $5.67 |
| Average True Range (ATR) | 0.14 | 0.23 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 91.46 | 95.52 |
Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.